Literature DB >> 22539783

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

Sarah Parish1, Alison Offer, Robert Clarke, Jemma C Hopewell, Michael R Hill, James D Otvos, Jane Armitage, Rory Collins.   

Abstract

BACKGROUND: Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol are established risk factors for vascular disease, but lipoprotein particle concentrations may be stronger determinants of risk. METHODS AND
RESULTS: Associations between vascular events and baseline concentrations of cholesterol fractions, apolipoproteins B and A(1), and lipoprotein particles assessed by nuclear magnetic resonance were considered in the Heart Protection Study randomized trial of simvastatin versus placebo (>5000 vascular events during 5.3 years of follow-up among 20 000 participants). Major occlusive coronary events were equally strongly associated with the cholesterol- and particle-based total LDL measures; adjusted hazard ratios per 1-SD-higher level were 1.25 (95% confidence interval [CI], 1.16-1.34) for LDL cholesterol, 1.22 (95% CI, 1.14-1.32) for non-HDL cholesterol, 1.23 (95% CI, 1.15-1.33) for apolipoprotein B, and 1.25 (95% CI, 1.16-1.35) for LDL particle number. Given the total LDL particle number, the distribution between small and large particles did not add predictive value. Associations of these different LDL-related measures were similar with arterial revascularization procedures but much weaker or nonexistent with ischemic stroke and other cardiac events (mainly heart failure). After adjustment for LDL particle number, the hazard ratios for major occlusive coronary event per 1-SD-higher level were 0.91 (95% CI, 0.86-0.96) for HDL cholesterol and 0.89 (95% CI, 0.85-0.93) for HDL particle number. Other cardiac events were inversely associated with total (hazard ratio, 0.84; 95% CI, 0.79-0.90) and small (0.82; 95% CI, 0.76-0.89) HDL particle number but only very weakly associated with HDL cholesterol (0.94; 95% CI, 0.88-1.00).
CONCLUSIONS: In a population at 2% average coronary event risk per year, cholesterol, apolipoprotein, and particle measures of LDL were strongly correlated and had similar predictive values for incident major occlusive vascular events. It is unclear whether the associations between HDL particle numbers and other cardiac events represent a causal or reverse-causal effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539783     DOI: 10.1161/CIRCULATIONAHA.111.073684

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  74 in total

1.  LDL and HDL transfer rates across peripheral microvascular endothelium agree with those predicted for passive ultrafiltration in humans.

Authors:  C Charles Michel; M Nazeem Nanjee; Waldemar L Olszewski; Norman E Miller
Journal:  J Lipid Res       Date:  2014-11-14       Impact factor: 5.922

2.  Carotid Artery Intima-Media Thickness in Young Adults with Family History of Coronary Artery Disease.

Authors:  Kanimozhi Sadasivam; Poornima Nagarajan; Indira Durai; Meenakshi Sundari; Saravanan Ayyavoo; Thilagavathi Ramamoorthy
Journal:  J Clin Diagn Res       Date:  2015-09-01

3.  Refocusing the AIM on HDL in the metabolic syndrome.

Authors:  Robert W McGarrah
Journal:  Atherosclerosis       Date:  2016-07-02       Impact factor: 5.162

4.  Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.

Authors:  Graziella E Ronsein; Patrick M Hutchins; Daniel Isquith; Tomas Vaisar; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

Review 5.  Clinical and biological relevance of statin-mediated changes in HDL metabolism.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

6.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

7.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

8.  Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.

Authors:  James D Otvos; John R Guyton; Margery A Connelly; Sydney Akapame; Vera Bittner; Steven L Kopecky; Megan Lacy; Santica M Marcovina; Joseph B Muhlestein; William E Boden
Journal:  J Clin Lipidol       Date:  2018-01-12       Impact factor: 4.766

9.  Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.

Authors:  Katya B Rubinow; Tomas Vaisar; Jing H Chao; Jay W Heinecke; Stephanie T Page
Journal:  J Clin Lipidol       Date:  2018-04-30       Impact factor: 4.766

10.  Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Authors:  Ying Zhang; Alicia J Jenkins; Arpita Basu; Julie A Stoner; Maria F Lopes-Virella; Richard L Klein; Timothy J Lyons
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.